Table 1.
Baseline characteristics of the study cohort prior to ETI.
| Age | 27.56 yrs (SD ± 12.29 yrs; range: 12–56 yrs) | |
| <18 yrs | 17 (Mean 14.8 yrs, SD ± 1.5 yrs) | |
| >18 yrs | 52 (Mean 31.4 yrs, SD ± 11.1 yrs) | |
| Sex | f | 27 (39%) |
| m | 42 (61%) | |
| Mutation | F508del homozygous | 39 (57%) |
| F508del heterozygous | 29 (42%) | |
| other | 1 (1%) | |
| CF-related diabetes | yes | 24 (35%) |
| no | 45 (65%) | |
| Pretreatment with CFTR modulator other than ETI | Iva | 8 (11%) |
| Teza + Iva | 17 (25%) | |
| Luma + Iva | 3 (4%) | |
| FEV1 | 69.3% (SD ± 21.3%; range 27–108%) | |
| >80% | 25 (Mean 92.1%, SD ± 8.2%) | |
| <80% | 44 (Mean 56.3%, SD ± 14.0%) | |
| Pseudomonas aeruginosa colonization | yes | 33 (48%) |
| no | 36 (52%) | |